Want to see EXOZ full AI Analyst Report?
EXOZ Stock Chart & Stats
$7.17
$0.20(4.55%)
At close: 4:00 PM EDT
$7.17
$0.20(4.55%)
Day’s Range― - ―
52-Week Range$4.35 - $18.40
Previous Close$4.6
Volume4.70K
Average Volume (3M)6.74K
Market Cap
$56.62M
Enterprise Value$68.44
Total Cash (Recent Filing)$5.65M
Total Debt (Recent Filing)$1.09M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding9,281,359
10 Day Avg. Volume9,737
30 Day Avg. Volume6,735
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageDebt has declined from about $1.24 million in 2025 to $0.74 million TTM, while debt-to-equity near 0.20 indicates leverage is not excessive relative to equity. This provides some financial flexibility as the company funds ongoing research and pipeline development.
Non-dilutive NIH FundingThe NIH award supplies two years of research funding without issuing shares, supporting rare cannabinoid production, analog development, and preclinical testing. The broader $19.7 million non-dilutive funding base can extend research capacity and strengthen the company’s ability to attract development partners.
Pipeline Development SupportCapital raised for NCT commercialization and additional product candidates supports progression from research toward commercial applications. Continued investment in nutraceutical and therapeutic programs may broaden the pipeline and create multiple routes to future revenue if development milestones are achieved.
Bears Say
No Revenue And Widening LossesNo reported revenue across the provided periods and widening net losses show that the business has not yet established commercial monetization. Persistent negative EBIT, EBITDA, and net income indicate substantial execution risk before the pipeline can produce recurring operating revenue.
Persistent Cash BurnOperating and free cash flow remain materially negative, requiring the company to secure outside funding to sustain operations and research. Although burn improved versus 2024, the continuing outflow can pressure liquidity and limit flexibility if capital markets or grant funding do not keep pace.
Equity Dilution And Warrant OverhangRepeated equity offerings provide funding but increase the share base, while attached warrants can create additional future dilution. The reset feature may also make the instruments more burdensome if shares are sold below the stated threshold, complicating long-term capital allocation and ownership economics.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $4.35 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
eXoZymes’s market cap is $56.62M.
When is eXoZymes’s upcoming earnings report date?
eXoZymes’s upcoming earnings report date is Nov 12, 2026 which is in 41 days.
How were eXoZymes’s earnings last quarter?
eXoZymes released its earnings results on Aug 20, 2026. The company reported -$0.332 earnings per share for the quarter.
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 9,281,359 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
eXoZymes reported an EPS of -$0.332 in its last earnings report. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
eXoZymes Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
eXoZymes
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
EXOZ Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
15.74% Insiders
0.45% Mutual Funds
― Other Institutional Investors
82.52% Public Companies and
Individual Investors